Contenu connexe



  2. References
  3. • A chronic progressive neuro-degenarative disease • Affects the dopamine producing neurone of the basal ganglia at the area called substantia nigra • Due to imbalance in two neurotransmitters – Dopamine – Acetylcholine • Dopamine low, Ach high
  4. • Dopamine play inhibitory role on cholinergic neurons in the area • ↓sed dopamine → elevated conc. Of Ach • elevated conc. Of Ach → unctrolled muscle contraction. • PKD is characterized by; – Tremors – Muscular rigidity – Bradykinesia (slowness in initiating and carrying out voluntary movements), and – Postural and gait abnormalities.
  5. Treatment aims • Elevating activity of dopaminergic neurons – Replacing dopamine – Stimulating dopamine production – Preventing dopamine breakdown • Reducing activity of Ach – Blocking receptors
  6. Dopamine replacement Levodopa [lee-voe-DOE-pa] • Is a metabolic precursor of dopamine MOA • levodopa, is actively transported into the CNS and is converted to dopamine in the brain • Large doses of levodopa are required, because much of the drug is decarboxylated to dopamine in the periphery.
  7. Carbidopa [kar-bi-DOE-pa] • The effects of levodopa on the CNS can be greatly enhanced by coadministering carbidopa a dopa decarboxylase inhibitor that does not cross the blood-brain barrier. • Carbidopa diminishes the metabolism of levodopa in the gastrointestinal tract and peripheral tissues; thus, it increases the availability of levodopa to the CNS • The addition of carbidopa lowers the dose of levodopa needed by • four- to five-fold and, consequently, decreases the severity of the side effects arising from peripherally formed dopamine.
  8. • Actions: Levodopa decreases the rigidity, tremors, and other symptoms of parkinsonism. • Therapeutic uses: Levodopa in combination with carbidopa is a potent and efficacious drug regimen currently • available to treat Parkinson's disease. In approximately two-thirds of patients with Parkinson's disease, • levodopa–carbidopa treatment substantially reduces the severity of the disease for the first few years of • treatment. Patients then typically experience a decline in response during the third to fifth year of therapy.
  9. • PK • Absorption and metabolism: The drug is absorbed rapidly from the small intestine (when empty of food). • Levodopa has an extremely short half-life (1 to 2 hours), which causes fluctuations in plasma concentration. • Ingestion of meals, particularly if high in protein, interferes with the transport of levodopa into the CNS. • Large, neutral amino acids (for example, leucine and isoleucine) compete with levodopa for absorption from the gut and for transport across the blood-brain barrier. • Thus, levodopa should be taken on an empty stomach, typically 45 minutes before a meal. • Withdrawal from the drug must be gradual.
  10. Selegiline [seh-LEDGE-ah-leen] • also called deprenyl [DE-pre-nill], MOA • Selectively inhibits MAO Type B (which metabolizes dopamine) at low to moderate doses • Does not inhibit MAO Type A (which metabolizes norepinephrine and serotonin) • By decreasing the metabolism of dopamine, selegiline increase dopamine levels in the brain
  11. • Administered orally • Metabolized to Methamphetamine and amphetamine, whose stimulating properties may produce insomnia if the drug is administered later than mid afternoon. Adverse effects • severe hypertension.
  12. Rasagiline [ra-SA-gi-leen] • Irreversible and selective inhibitor of brain monoamine oxidase Type B. • Has five times the potency of selegiline. • Unlike selegiline, rasagiline is not metabolized to an amphetamine like substance.
  13. Catechol-O-methyltransferase inhibitors • methylation of levodopa by catechol-O- methyltransferase (COMT) to 3-O-methyldopa is a minor pathway for levodopa metabolism. • when peripheral dopamine decarboxylase activity is inhibited by carbidopa, a significant concentration of 3-O-methyldopa is formed that competes with levodopa for active transport into the CNS
  14. • Entacapone [en-TA-ka-pone] or Tolcapone [TOLE-ka-pone] • Are nitrocatechol derivatives that selectively and reversibly inhibit COMT • Inhibits COMT → ↓sed plasma con. of 3-O- methyldopa, increased central uptake of levodopa, and greater concentrations of brain dopamine • Reduce the symptoms of “wearing-off ” phenomena seen in patients on levodopa– carbidopa
  15. • Pharmacokinetics: • Administered orally • Absorption occurs readily and is not influenced by food. • Are extensively bound to plasma albumin (>98 percent), with limited volumes of distribution. • Tolcapone but not entacapone penetrates the blood- brain barrier and inhibits COMT in the CNS. • Tolcapone has a relatively long duration of action (probably due to its affinity for the enzyme) compared to entacapone, which requires more frequent dosing. • Both drugs are extensively metabolized and eliminated in feces and urine. • Dosage may need to be adjusted in patients with moderate or severe cirrhosis.
  16. Adverse effects: • Diarrhea • Postural hypotension, • Nausea & anorexia, • Dyskinesias • Hallucination • Sleep disorders. • Fulminating hepatic necrosis is associated with tolcapone use.
  17. Dopamine-receptor agonists Include; • Pramipexole & ropinirole • Apormorphine & Rotigotine • Amantadine
  18. • Pramipexole [pra-mi-PEX-ole] and ropinirole [roe-PIN-i-role] are agonists at dopamine receptors. • Apomorphine [A-po-mor-feen] and rotigotine [ro-TI-go-teen] are newer dopamine agonists available in injectable and transdermal delivery systems, respectively
  19. Amantadine • Amantadine has several effects on a number of neurotransmitters implicated in causing parkinsonism, including; – Increasing the release of dopamine, – Blockading cholinergic receptors, and – Inhibiting the N-methyl-D-aspartate (NMDA) type of glutamate receptors. • Current evidence supports an action at NMDA receptors as the primary action at therapeutic concentrations
  20. Adverse effects • Agitation • Confusion • Hallucinations • At high doses, it may induce acute toxic psychosis. • Orthostatic hypotension • Urinary retention • Peripheral edema • Dry mouth also may occur.
  21. Antimuscarinic agents • Benztropine [BENZ-tro-peen] • Trihexyphenidyl [tri-hex-ee FEN-i-dill] • Procyclidine [pro-CY-cli-deen] • Biperiden [bi-PER-i den] MOA • Blocks cholinergic transmission producing effects similar to augmentation of dopaminergic transmission
  22. Adverse effects • pupillary dilation, • confusion, • hallucination, sinus • tachycardia, • urinary retention, • constipation, and • dry mouth.